Skip to main content
Caplight Logo









Exciva GmbH

Exciva GmbH

Private
HeidelbergHealthcare & Life Scienceshttps://www.exciva.com/

Last Round

Series B

Jan 20, 2026

Total Funding Raised

$72M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Exciva GmbH is a biopharmaceutical company that develops clinical-stage therapeutics for neuropsychiatric conditions, with a primary focus on agitation in patients with Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalAlzheimer's diseaseneuropsychiatric conditionscentral nervous systemCNSclinical trialsdrug developmentcombination therapybiotechagitation treatmenttherapeutic compoundsdementia caredrug discoveryneuroscienceclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Exciva GmbH Comparables

Compare Exciva GmbH with similar companies based on industry and business-model similarity.

Exciva GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
H. Lundbeck A/S
79%
IGC Pharma, Inc.
78%
Johnson & Johnson
77%

Exciva GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 20, 2026
Series AOct 26, 2021

Exciva GmbH Investors

Notable investors and investment history

Exciva GmbH investors
InvestorRounds
EQT Life SciencesSeries B
Dolby Family VenturesSeries B
GimvSeries B
Andera PartnersSeries B, Seed, Series A
Fountain Healthcare PartnersSeries B
Landesbank Baden-WürttembergSeries B
Cure8 VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 20, 2026

    $59M round completed.

  • Jun 1, 2025

    Monthly visitors grew 63% MoM, from 319 to 521.

Exciva GmbH Filings

Explore SEC and related filing metadata, where available.

Exciva GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Exciva GmbH's valuation, stock price, and market status.

Is Exciva GmbH a public or private company?

Exciva GmbH is a private company.

What is the current stock price of Exciva GmbH?

Exciva GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is Exciva GmbH worth (valuation)?

Valuation information for Exciva GmbH is not publicly available.

Can I buy Exciva GmbH stock?

Exciva GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Exciva GmbH's last funding round?

Exciva GmbH's most recent funding round was Series B on January 20, 2026.

Who are the main investors in Exciva GmbH?

Key investors in Exciva GmbH include EQT Life Sciences, Gimv.

Will Exciva GmbH IPO soon?

No public IPO plans have been announced for Exciva GmbH.

How can I track Exciva GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Exciva GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHeidelberg
Employee Range2
Year Founded2016
Last FundingJan 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?